iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus Lifesciences bags final USFDA approval for Famotidine Injection

23 Nov 2022 , 02:58 PM

The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) final approval to market Famotidine Injection USP, 40 mg/4 mL (10 mg/mL) and 200 mg/20 mL (10 mg/mL) multiple-dose vials.

Famotidine Injection is used to treat stomach and intestine ulcers, as well as to keep intestinal ulcers from returning after they have healed. This medication is also used to treat conditions affecting the stomach and throat (oesophagus), such as erosive esophagitis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

According to IQVIA data, Famotidine Injection had annual sales of USD 1.9 million in the United States (IQVIA MAT Sep 2022). The drug will be produced at the group’s injectable manufacturing facility in Jarod, India, near Vadodara.

Since the beginning of the filing process in FY 2003-04, the group has received 333 approvals and has filed over 431 ANDAs.

At around 3.01 PM, Zydus Lifesciences was trading at Rs394.10 up by 0.42% from its previous closing of Rs392.45 on the BSE. The scrip touched intraday high and low of Rs395.30 and Rs390.85 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Cadila Healthcare News
  • Cadila Healthcare Share
  • Cadila Healthcare Stock
  • Cadila Healthcare Updates
  • Zydus Lifesciences Approval
  • Zydus Lifesciences news
  • Zydus Lifesciences Stock
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.